Arbutus Biopharma Taken Off Of Chardan's Sell List
June 16, 2016 at 09:29 AM EDT
Chardan has upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) to Neutral following its underperformance versus Arrowhead Pharmaceuticals ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.